Abstract
A prospective randomized feasibility study was carried out on 10 patients undergoing IVF treatment using a single-dose LHRH antagonist protocol (cetrorelix, Cetrotide®) with clomiphene citrate in combination with either human menopausal gonadotrophin (HMG) ( n = 5) or recombinant human FSH (rFSH) ( n = 5). Both treatment-groups, HMG and rFSH, were comparable with regard to age (33.2 ± 2.6 versus 34.4 ± 4.0 years) BMI (23.2 ± 2.6 versus 22.7 ± 1.6) and cause of infertility. They yielded comparable results concerning gonadotrophin dose (19.8 ± 8.7 versus 17.0 ± 8.9), stimulation days (6.5 ± 2.0 versus 5.8 ± 1.9) and live births (one versus two). No premature LH surge (LH >10 IU/ml and progesterone >1 ng/ml) occurred. The overall baby take-home rate was 30%. In a small number of patients, cetrorelix could be shown to effectively prevent premature LH surges in stimulation protocols combining clomiphene with gonadotrophins with an excellent baby take-home rate per started cycle of 30%.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
